Ono’s BMS-Partnered Oral Gastric Cancer Drug Meets Primary Endpoint in Phase 2 Trial

ONO-4578; EP4 antagonist; gastric cancer; Opdivo; nivolumab; Bristol-Myers Squibb; phase 2; progression-free survival; chemotherapy; HER2-negative; advanced; recurrent

Novartis Bets on Covalent Chemistry in $1B Matchpoint Therapeutics Deal

Novartis; Matchpoint Therapeutics; covalent chemistry; exclusive option and license agreement; inflammatory diseases; oral inhibitors; Advanced Covalent Exploration platform; drug development; biotechnology partnerships

Advancing Aseptic Manufacturing: GRAM’s Vision for the Future of Sterile Drug Production

Aseptic manufacturing , Isolator technology, Automation and robotics, Flexible fill-finish capabilities, Advanced drug delivery systems, Regulatory compliance (Annex 1), Strategic partnerships, Patient-centric solutions

ESMO24: AstraZeneca’s Imfinzi and Imjudo Combination Doubles 5-Year Overall Survival Rate in Advanced Liver Cancer

AstraZeneca, Imfinzi (durvalumab), Imjudo (tremelimumab), Advanced Liver Cancer, Unresectable Hepatocellular Carcinoma (HCC), 5-Year Overall Survival Rate, ESMO24